Amiodarone and torsades de pointes in patients with advanced heart failure (Q42277569)

19 October 2017

Amiodarone and torsades de pointes in patients with advanced heart failure (English)

1 reference

19 October 2017

0 references

1 reference

1 reference

Middlekauff HR

1

1 reference

19 October 2017

Stevenson WG

series ordinal

2

1 reference

19 October 2017

Saxon LA

series ordinal

3

1 reference

19 October 2017

Stevenson LW

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

American Journal of Cardiology

19 October 2017

1 reference

19 October 2017

76

1 reference

19 October 2017

7

1 reference

19 October 2017

499-502

1 reference

Sudden death prevention in patients with advanced ventricular dysfunction

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Amiodarone and post-MI patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

"Les torsades de pointes": an unusual ventricular arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Diverse mechanisms of unexpected cardiac arrest in advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

"Late" proarrhythmia due to quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Acute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980138-6

10.1016/S0002-9149(99)80138-6

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference